Clinical Trial

SAPT Versus DAPT in Incomplete Revascularization After CABG

Study acronym: SDAT-IRC
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The study aims to compare the efficacy of dual antiplatelet therapy (DAPT) over single antiplatelet therapy (SAPT) in patients with incomplete revascularization after coronary artery bypass graft surgery (CABG). Before hospital discharge, patients will be 1:1 randomized to SAPT (acetylsalicylic acid 100 mg/die) or DAPT (acetylsalicylic acid 100 mg/die + ticagrelor 90 mg bis in die). DAPT will be continued for 12 months, and ticagrelor will be withdrawn thereafter. Primary endpoint is the evaluation of cardiac-related mortality at 5 years from hospital discharge.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2018-12-28; most recent amendment 2022-07-19.
Trial Details
NCT Number NCT03789916
Lead Sponsor Campus Bio-Medico University
Conditions Coronary Artery Disease
Enrollment 800 participants
Start Date 2019-01-02
Primary Completion 2021-08-01 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2022-07-21